Patients with localized muscle-invasive bladder cancer (MIBC) who received radiation plus the immune checkpoint inhibitors (ICIs) durvalumab (Imfinzi) and tremelimumab (Imjudo) had durable responses ...

Patients with localized muscle-invasive bladder cancer (MIBC) who received radiation plus the immune checkpoint inhibitors (ICIs) durvalumab (Imfinzi) and tremelimumab (Imjudo) had durable responses ...

The immune systems of cancer patients are highly disrupted, with those who have a higher number of immune cells in their blood having a better survival rate, finds a new study that uses a pioneering ...

February is National Cancer Awareness Month, a time to amplify discussions on lesser- known but equally devastating ...

Research highlights the importance of a nutritious diet in cancer prevention, emphasizing protein-rich foods, berries, turmeric, green tea, and cruciferous vegetables. These foods help support ...

According to Paget's “soil-seed” hypothesis, the scalp provided a favorable environment for colonizing and surviving gallbladder cancer cells. In addition, the interaction between tumor cells and ...

The tumor was removed successfully". Dr. KIM added that the patient visited the hospital suffering from sudden abdominal pain and acidity. After thorough CT and MRI scans and a biopsy, it was ...

Polyps in the gallbladder may not cause any symptoms. Depending on the type of polyps, they can be benign, be a sign of inflammation, or potentially lead to cancer. Polyps are abnormal tissue growths.

Adjuvant cytokine-induced killer cell immunotherapy in hepatocellular carcinoma: Extended follow-up of a randomized controlled trial and post-treatment immune cell profiling. Nivolumab (NIVO) plus ...

Radiomics-based prediction of HCC response to atezolizumab/bevacizumab. This is an ASCO Meeting Abstract from the 2025 ASCO Gastrointestinal Cancers Symposium. This ...

Cite this: Biological Markers in the Diagnosis of Recurrent Bladder Cancer: An Overview - Medscape - Jan 01, 2008. Bladder cancer is considered to be one of the most common genitourinary cancers.

“With every case that you find and a cancer marker is detected, it’s checked off as a savings,” Scheeler said. This year, 87% of employers are paying for more types of cancer tests, the ...